CS-121

N/A

Report date: 2026/02/12 20:00:14

Base Information

Drug NameCS-121
Drug Alias NameCS-121
ClassificationCell and gene therapy > Gene therapy > LNPCell and gene therapy > Gene therapy > Gene editing > Base editing
Mechanisms of ActionApolipoprotein C-III modulators
TargetsApolipoprotein C-III
Therapy Area/IndicationsHypertriglyceridemiaHyperlipoproteinemia Type I
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCorrectSequence Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCorrectSequence Therapeutics Co LtdShanghai Jiao Tong University School of Medicine
Inactive CompaniesN/A
Active IndicationsHypertriglyceridemiaHyperlipoproteinemia Type I
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A